The transcriptional profiling of human in vivo-generated plasma cells identifies selective imbalances in monoclonal gammopathies

PLoS One. 2017 Aug 17;12(8):e0183264. doi: 10.1371/journal.pone.0183264. eCollection 2017.

Abstract

Plasma cells (PC) represent the heterogeneous final stage of the B cells (BC) differentiation process. To characterize the transition of BC into PC, transcriptomes from human naïve BC were compared to those of three functionally-different subsets of human in vivo-generated PC: i) tonsil PC, mainly consisting of early PC; ii) PC released to the blood after a potent booster-immunization (mostly cycling plasmablasts); and, iii) bone marrow CD138+ PC that represent highly mature PC and include the long-lived PC compartment. This transcriptional transition involves subsets of genes related to key processes for PC maturation: the already known protein processing, apoptosis and homeostasis, and of new discovery including histones, macromolecule assembly, zinc-finger transcription factors and neuromodulation. This human PC signature is partially reproduced in vitro and is conserved in mouse. Moreover, the present study identifies genes that define PC subtypes (e.g., proliferation-associated genes for circulating PC and transcriptional-related genes for tonsil and bone marrow PC) and proposes some putative transcriptional regulators of the human PC signatures (e.g., OCT/POU, XBP1/CREB, E2F, among others). Finally, we also identified a restricted imbalance of the present PC transcriptional program in monoclonal gammopathies that correlated with PC malignancy.

MeSH terms

  • Animals
  • Gene Expression Profiling*
  • Humans
  • Mice
  • Oligonucleotide Array Sequence Analysis
  • Paraproteinemias / genetics*
  • Plasma Cells / immunology*
  • Real-Time Polymerase Chain Reaction
  • Transcription, Genetic*

Grants and funding

This study has been supported by grants from the Fondo de Investigaciones Sanitarias of Spain (PI11/02193 to JAB and PI15/01147 to AC-C), the Planes Estatales I+D+i 2008-2011 and 2013-2016 from the Fondos Europeos de Desarrollo Regional. LMV is the recipient of a Miguel Servet I contract (CP15/00180) from Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, and Fondo Social Europeo 2014-2020. (http://www.isciii.es/).